Open Actively Recruiting

TK216 in Patients With Relapsed or Refractory Ewing Sarcoma

About

Brief Summary

This study is being done to find out if a new drug called TK216 helps in the treatment for Ewing Sarcoma which is a type of cancer of the bone. The purpose of the phase I part of this study is to test the safety of TK216 in the treatment of advanced cancer. The study will try to find the highest dose of TK216 that can be given without causing severe side effects. The dose you will get will depend on when you enter the study.

Primary Purpose
Treatment
Study Type
Interventional
Phase
Phase I

Eligibility

Gender
All
Healthy Volunteers
No
Minimum Age
8 Years
Maximum Age
N/A

Adult subjects with Ewing Sarcoma that had improved and then returned (relapsed) or that is resistant to treatment (refractory)\n\n For more information about the eligibility criteria for this trial, refer to the Health Professional version.

Inclusion Criteria:

  • Histologically or cytologically confirmed diagnosis of Ewing sarcoma (including ESFT) in subjects with relapsed or refractory disease who have failed standard therapy

Exclusion Criteria:

  • Symptomatic brain metastases

Join this Trial

Contact our clinical trial navigators for opportunities that may be suitable for you
Study Stats
Protocol No.
16-000073
Category
Oncology
Pediatrics
Contact
Rubi Arias
Location
  • UCLA Westwood
For Providers
NCT No.
NCT02657005
For detailed technical eligibility, visit ClinicalTrials.gov.